二甲双胍联合多西他赛治疗乳腺癌并2型糖尿病临床研究
|
摘要
目的探讨二甲双胍联合多西他赛治疗乳腺癌并2型糖尿病的临床效果及对患者血清相关因子的影响。方法选择医院2015年3月至2016年3月收治的乳腺癌并2型糖尿病患者76例,按治疗方法的不同分为对照组和试验组,各38例。两组患者均予多西他赛,试验组患者在此基础上予二甲双胍。结果与治疗前比较,两组患者治疗后血清糖化血红蛋白(HbA1C)、癌胚抗原(CEA)、血管内皮生长因子(VEGF)、视黄醇结合蛋白4(RBP4)水平和胱天蛋白酶-3(Caspase-3)表达水平显著降低,胱天蛋白酶-9(Caspase-9)表达水平显著升高(P <0. 05),且试验组显著优于对照组(P <0. 05);试验组临床受益率为94. 74%,显著高于对照组的78. 95%(P <0. 05);两组不良反应发生率无显著差异(P> 0. 05)。结论二甲双胍联合多西他赛治疗乳腺癌合并2型糖尿病可提高临床受益率,改善HbA1C,CEA,VEGF,RBP4,Caspase-3及Caspase-9水平,且不增加不良反应。
Objective To investigate the clinical effect of metformin combined with docetaxel in the treatment of patients with breast cancer complicated with type 2 diabetes mellitus( T2 DM) and its effect on serum related factors. Methods Totally 76 patients with breast cancer complicated with T2 DM admitted to our hospital from March 2015 to March 2016 were selected and divided into the control group and the experimental group according to different treatment methods,38 cases in each group. The patients in the two groups were given docetaxel,on this basis,the patients in the experimental group were given metformin. Results Compared with before treatment,the levels of serum glycosylated hemoglobin( Hb A1 C),carcinoembryonic antigen( CEA),vascular endothelial growth factor( VEGF),retinol binding protein 4( RBP4) and Caspase-3 in the two groups were significantly lower after treatment,while the levels of Caspase-9 in the two groups were significantly higher after treatment,and those in the experimental group were significantly better than those in the control group( P < 0. 05). The clinical benefit rate of the experimental group was 94. 74%,which was significantly higher than 78. 95% of the control group( P < 0. 05). There was no significant difference in the incidence of adverse reactions between the two groups( P > 0. 05). Conclusion Metformin combined with docetaxel in the treatment of with breast cancer complicated with T2 DM can increase the clinical benefit rate,improve the levels of HbA1 C,CEA,VEGF,RBP4,Caspase-3 and Caspase-9 without increasing the adverse reactions.
Objective To investigate the clinical effect of metformin combined with docetaxel in the treatment of patients with breast cancer complicated with type 2 diabetes mellitus( T2 DM) and its effect on serum related factors. Methods Totally 76 patients with breast cancer complicated with T2 DM admitted to our hospital from March 2015 to March 2016 were selected and divided into the control group and the experimental group according to different treatment methods,38 cases in each group. The patients in the two groups were given docetaxel,on this basis,the patients in the experimental group were given metformin. Results Compared with before treatment,the levels of serum glycosylated hemoglobin( Hb A1 C),carcinoembryonic antigen( CEA),vascular endothelial growth factor( VEGF),retinol binding protein 4( RBP4) and Caspase-3 in the two groups were significantly lower after treatment,while the levels of Caspase-9 in the two groups were significantly higher after treatment,and those in the experimental group were significantly better than those in the control group( P < 0. 05). The clinical benefit rate of the experimental group was 94. 74%,which was significantly higher than 78. 95% of the control group( P < 0. 05). There was no significant difference in the incidence of adverse reactions between the two groups( P > 0. 05). Conclusion Metformin combined with docetaxel in the treatment of with breast cancer complicated with T2 DM can increase the clinical benefit rate,improve the levels of HbA1 C,CEA,VEGF,RBP4,Caspase-3 and Caspase-9 without increasing the adverse reactions.
引文
[1]刘桂红,周卫华,张玉娜,等.乳腺癌合并2型糖尿病患者的临床病理特征及预后分析[J].河北医科大学学报,2016,37(3):249-251.
[2]肖康,冯其乡.二甲双胍联合西格列汀治疗2型糖尿病伴代谢综合征疗效评价[J].中国药业,2018,27(7):47-49.
[3]曹秀霞.多西他赛联合表柔比星治疗中晚期乳腺癌45例临床研究[J].中国药业,2017,26(15):54-56.
[4]中国抗癌协会.乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(9):692-754.
[5]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):292-344.
[6]汪颖,贾卫娟,饶南燕,等.含卡培他滨方案一线或后线治疗晚期乳腺癌的疗效比较[J].中华肿瘤防治杂志,2016,23(15):1006-1010.
[7]高梅娟,张丽杰,于春梅.抗糖尿病药物与乳腺癌相关性研究[J].中国预防医学杂志,2016,17(6):442-446.
[8]王艳妮,段建芳,彭燕,等.老年2型糖尿病患者应用二甲双胍的疗效及安全性分析[J].中华老年多器官疾病杂志,2018,17(1):16-20.
[9]李云霞.多西他赛治疗紫杉醇耐药乳腺癌的疗效[J].现代仪器与医疗,2016,22(4):31-32.
[10]张曙晴,李洪彬,张骆军,等.2型糖尿病患者糖化血红蛋白水平与胰岛素分泌及胰岛素抵抗的关系[J].现代检验医学杂志,2016,31(2):108-111.
[11]张景岚,周广朋.2型糖尿病胰岛素抵抗与RBP4、游离脂肪酸临床相关研究[J].四川医学,2016,37(9):960-962.
[12]WU J,CAI Y,LI M,et al.Oxymatrine Promotes S-Phase Arrest and Inhibits Cell Proliferation of Human Breast Cancer Cells in Vitro through Mitochondria-Mediated Apoptosis[J].Biological&Pharmaceutical Bulletin,2017,40(8):1232-1239.
[13]王琦,刘玉林,翟爱华,等.二甲双胍治疗多种类型肿瘤的研究进展[J].肿瘤研究与临床,2016,28(1):68-72.
[2]肖康,冯其乡.二甲双胍联合西格列汀治疗2型糖尿病伴代谢综合征疗效评价[J].中国药业,2018,27(7):47-49.
[3]曹秀霞.多西他赛联合表柔比星治疗中晚期乳腺癌45例临床研究[J].中国药业,2017,26(15):54-56.
[4]中国抗癌协会.乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(9):692-754.
[5]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):292-344.
[6]汪颖,贾卫娟,饶南燕,等.含卡培他滨方案一线或后线治疗晚期乳腺癌的疗效比较[J].中华肿瘤防治杂志,2016,23(15):1006-1010.
[7]高梅娟,张丽杰,于春梅.抗糖尿病药物与乳腺癌相关性研究[J].中国预防医学杂志,2016,17(6):442-446.
[8]王艳妮,段建芳,彭燕,等.老年2型糖尿病患者应用二甲双胍的疗效及安全性分析[J].中华老年多器官疾病杂志,2018,17(1):16-20.
[9]李云霞.多西他赛治疗紫杉醇耐药乳腺癌的疗效[J].现代仪器与医疗,2016,22(4):31-32.
[10]张曙晴,李洪彬,张骆军,等.2型糖尿病患者糖化血红蛋白水平与胰岛素分泌及胰岛素抵抗的关系[J].现代检验医学杂志,2016,31(2):108-111.
[11]张景岚,周广朋.2型糖尿病胰岛素抵抗与RBP4、游离脂肪酸临床相关研究[J].四川医学,2016,37(9):960-962.
[12]WU J,CAI Y,LI M,et al.Oxymatrine Promotes S-Phase Arrest and Inhibits Cell Proliferation of Human Breast Cancer Cells in Vitro through Mitochondria-Mediated Apoptosis[J].Biological&Pharmaceutical Bulletin,2017,40(8):1232-1239.
[13]王琦,刘玉林,翟爱华,等.二甲双胍治疗多种类型肿瘤的研究进展[J].肿瘤研究与临床,2016,28(1):68-72.